The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease (original) (raw)

References

  1. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353–356 (2002)
    Article ADS CAS Google Scholar
  2. Hardy, J. A. & Higgins, G. A. Alzheimer’s disease: the amyloid cascade hypothesis. Science 256, 184–185 (1992)
    Article ADS CAS Google Scholar
  3. Ising, C., Stanley, M. & Holtzman, D. M. Current thinking on the mechanistic basis of Alzheimer’s and implications for drug development. Clin. Pharmacol. Ther. 98, 469–471 (2015)
    Article CAS Google Scholar
  4. Selkoe, D. J. The therapeutics of Alzheimer’s disease: where we stand and where we are heading. Ann. Neurol. 74, 328–336 (2013)
    Article CAS Google Scholar
  5. Cummings, J. L., Morstorf, T. & Zhong, K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6, 37 (2014)
    Article Google Scholar
  6. Doody, R. S. et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 311–321 (2014)
    Article CAS Google Scholar
  7. Salloway, S. et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 370, 322–333 (2014)
    Article CAS Google Scholar
  8. Ferrero, J. et al. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimers Dement (N Y) (in the press)
  9. Sevigny, J. et al. Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial. Alzheimer Dis. Assoc. Disord. 30, 1–7 (2016)
    Article CAS Google Scholar
  10. Landau, S. M. et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J. Nucl. Med. 54, 70–77 (2013)
    Article CAS Google Scholar
  11. Banks, W. A. et al. Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer’s disease. Peptides 23, 2223–2226 (2002)
    Article CAS Google Scholar
  12. Levites, Y. et al. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer’s disease mouse models. FASEB J. 20, 2576–2578 (2006)
    Article CAS Google Scholar
  13. Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916–919 (2000)
    Article CAS Google Scholar
  14. Bohrmann, B. et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J. Alzheimers Dis. 28, 49–69 (2012)
    Article CAS Google Scholar
  15. Villemagne, V. L. et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 12, 357–367 (2013)
    Article CAS Google Scholar
  16. Ostrowitzki, S. et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch. Neurol. 69, 198–207 (2012)
    Article Google Scholar
  17. Sperling, R. et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241–249 (2012)
    Article CAS Google Scholar
  18. Sperling, R. A. et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 7, 367–385 (2011)
    Article Google Scholar
  19. Barakos, J. et al. MR imaging features of amyloid-related imaging abnormalities. AJNR Am. J. Neuroradiol. 34, 1958–1965 (2013)
    Article CAS Google Scholar
  20. Zago, W. et al. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities. Alzheimers Dement. 9 (Suppl), S105–S115 (2013)
    Article Google Scholar
  21. Wang, A., Das, P., Switzer, R. C., III, Golde, T. E. & Jankowsky, J. L. Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 31, 4124–4136 (2011)
    Article CAS Google Scholar
  22. Boche, D. et al. Consequence of Abeta immunization on the vasculature of human Alzheimer’s disease brain. Brain 131, 3299–3310 (2008)
    Article CAS Google Scholar
  23. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101–112 (2007)
    Article CAS Google Scholar
  24. Kayed, R. & Lasagna-Reeves, C. A. Molecular mechanisms of amyloid oligomers toxicity. J. Alzheimers Dis. 33 (Suppl 1), S67–S78 (2013)
    Article Google Scholar
  25. Benilova, I., Karran, E. & De Strooper, B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat. Neurosci. 15, 349–357 (2012)
    Article CAS Google Scholar
  26. Koffie, R. M. et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012–4017 (2009)
    Article ADS CAS Google Scholar
  27. Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat. Med. 14, 837–842 (2008)
    Article CAS Google Scholar
  28. Condello, C., Yuan, P., Schain, A. & Grutzendler, J. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques. Nat. Commun. 6, 6176 (2015)
    Article ADS CAS Google Scholar
  29. Jin, M. et al. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration. Proc. Natl Acad. Sci. USA 108, 5819–5824 (2011)
    Article ADS CAS Google Scholar
  30. Kastanenka, K. et al. Amelioration of calcium dyshomeostasis by immunotherapy with BIIB037 in Tg2576 mice. Alzheimers Dement. 9, P508 (2013)
    Article Google Scholar
  31. Jarosz-Griffiths, H. H., Noble, E., Rushworth, J. V. & Hooper, N. M. Amyloid-β receptors: the good, the bad, and the prion protein. J. Biol. Chem. 291, 3174–3183 (2016)
    Article CAS Google Scholar
  32. Morkuniene, R. et al. Small Aβ1-42 oligomer-induced membrane depolarization of neuronal and microglial cells: role of _N_-methyl-d-aspartate receptors. J. Neurosci. Res. 93, 475–486 (2015)
    Article CAS Google Scholar
  33. Um, J. W. et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron 79, 887–902 (2013)
    Article CAS Google Scholar
  34. Derby, C. A. et al. Screening for predementia AD: time-dependent operating characteristics of episodic memory tests. Neurology 80, 1307–1314 (2013)
    Article Google Scholar
  35. Dubois, B. et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 9, 1118–1127 (2010)
    Article Google Scholar
  36. McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 7, 263–269 (2011)
    Article Google Scholar
  37. Eli Lilly and Company. Amyvid Prescribing Information. http://www.lilly.com. (2013)
  38. Clark, C. M. et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 11, 669–678 (2012)
    Article CAS Google Scholar
  39. Hock, C. et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med. 8, 1270–1275 (2002)
    Article CAS Google Scholar
  40. Tao, M. H. & Morrison, S. L. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol. 143, 2595–2601 (1989)
    CAS PubMed Google Scholar
  41. Johnson-Wood, K. et al. Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc. Natl Acad. Sci. USA 94, 1550–1555 (1997)
    Article ADS CAS Google Scholar

Download references

Acknowledgements

These studies were funded by Biogen. The authors thank the patients and their family members participating in the aducanumab studies, and the PRIME investigators (Supplementary Information) and staff conducting these studies. Medical writing support, under direction of the authors, was provided by A. Smith at Complete Medical Communications, and was funded by Biogen. We thank N. Pederson, J. Dolnikova and E. Garber for help in generating the recombinant antibodies, D. Fahrer, C. Quigley, M. Themeles, X. Zhang and P. Auluck for help in generating the histological data, and K. Mack for editorial support and coordination of the authors in combining the preclinical and clinical work in this manuscript.

Author information

Author notes

  1. Jeff Sevigny, Ping Chiao, Thierry Bussière and Paul H. Weinreb: These authors contributed equally to this work.
  2. Roger M. Nitsch and Alfred Sandrock: These authors jointly supervised this work.

Authors and Affiliations

  1. Biogen, Cambridge, 02142, Massachusetts, USA
    Jeff Sevigny, Ping Chiao, Thierry Bussière, Paul H. Weinreb, Leslie Williams, Robert Dunstan, Tianle Chen, Yan Ling, John O’Gorman, Fang Qian, Mahin Arastu, Mingwei Li, Sowmya Chollate, Melanie S. Brennan, Omar Quintero-Monzon, Robert H. Scannevin, H. Moore Arnold, Thomas Engber, Kenneth Rhodes, James Ferrero, Yaming Hang, Alvydas Mikulskis & Alfred Sandrock
  2. Neurimmune, Schlieren-Zurich, 8952, Switzerland
    Marcel Maier, Jan Grimm, Christoph Hock & Roger M. Nitsch
  3. Butler Hospital, Providence, Rhode Island, 02906, USA
    Stephen Salloway
  4. Institute for Regenerative Medicine, University of Zurich, Zurich, 8952, Switzerland
    Christoph Hock & Roger M. Nitsch

Authors

  1. Jeff Sevigny
    You can also search for this author inPubMed Google Scholar
  2. Ping Chiao
    You can also search for this author inPubMed Google Scholar
  3. Thierry Bussière
    You can also search for this author inPubMed Google Scholar
  4. Paul H. Weinreb
    You can also search for this author inPubMed Google Scholar
  5. Leslie Williams
    You can also search for this author inPubMed Google Scholar
  6. Marcel Maier
    You can also search for this author inPubMed Google Scholar
  7. Robert Dunstan
    You can also search for this author inPubMed Google Scholar
  8. Stephen Salloway
    You can also search for this author inPubMed Google Scholar
  9. Tianle Chen
    You can also search for this author inPubMed Google Scholar
  10. Yan Ling
    You can also search for this author inPubMed Google Scholar
  11. John O’Gorman
    You can also search for this author inPubMed Google Scholar
  12. Fang Qian
    You can also search for this author inPubMed Google Scholar
  13. Mahin Arastu
    You can also search for this author inPubMed Google Scholar
  14. Mingwei Li
    You can also search for this author inPubMed Google Scholar
  15. Sowmya Chollate
    You can also search for this author inPubMed Google Scholar
  16. Melanie S. Brennan
    You can also search for this author inPubMed Google Scholar
  17. Omar Quintero-Monzon
    You can also search for this author inPubMed Google Scholar
  18. Robert H. Scannevin
    You can also search for this author inPubMed Google Scholar
  19. H. Moore Arnold
    You can also search for this author inPubMed Google Scholar
  20. Thomas Engber
    You can also search for this author inPubMed Google Scholar
  21. Kenneth Rhodes
    You can also search for this author inPubMed Google Scholar
  22. James Ferrero
    You can also search for this author inPubMed Google Scholar
  23. Yaming Hang
    You can also search for this author inPubMed Google Scholar
  24. Alvydas Mikulskis
    You can also search for this author inPubMed Google Scholar
  25. Jan Grimm
    You can also search for this author inPubMed Google Scholar
  26. Christoph Hock
    You can also search for this author inPubMed Google Scholar
  27. Roger M. Nitsch
    You can also search for this author inPubMed Google Scholar
  28. Alfred Sandrock
    You can also search for this author inPubMed Google Scholar

Contributions

T.B., P.H.W., M.M., T.E., K.R., J.G. and R.M.N. designed the preclinical studies, and J.S., Y.L., J.G., J.F., C.H., R.M.N. and A.S. designed the clinical study. P.C. led the imaging implementation for the clinical study. T.C. and J.O. were clinical study statisticians. T.B., P.H.W., M.M., R.D., F.Q., M.A., M.L., S.C., M.S.B., O.Q.-M., R.H.S., H.M.A., T.E., J.G. and R.M.N. generated, analysed, and/or interpreted data from preclinical studies. T.B., P.H.W., M.M., R.D., F.Q., M.A., M.L., S.C., M.S.B., O.Q.-M., R.H.S., H.M.A., T.E., K.R., J.G., C.H., R.M.N. and A.S. critically reviewed preclinical sections of the manuscript. J.S., P.C., L.W., S.S., T.C., Y.L., J.O., J.F., Y.H., A.M., J.G., C.H., R.M.N. and A.S. analysed and interpreted clinical study data and critically reviewed clinical sections of the manuscript. All authors approved the final version of the manuscript for submission. Biogen and Neurimmune reviewed and provided feedback on the paper. The authors had full editorial control of the paper, and provided their final approval of all content.

Corresponding author

Correspondence toAlfred Sandrock.

Ethics declarations

Competing interests

J.S., P.C., T.B., P.H.W., L.W., R.D., T.C., Y.L., J.O., F.Q., M.A., M.L., S.C., M.S.B., O.Q.-M., R.H.S., H.M.A., T.E., K.R., J.F., Y.H., A.M. and A.S. are current or former employees and/or shareholders of Biogen. J.S. is an employee of F. Hoffmann-La Roche Ltd., Basel, Switzerland; R.D. is an employee of AbbVie Inc., Worcester, Massachusetts, USA; M.A. is an employee of Substantial Living, San Francisco, California, USA; M.L. is an employee of Novartis, Cambridge, Massachusetts, USA; S.C. is an employee of SynteractHCR, Carlsbad, California, USA; O.Q.-M. is an employee of Shire, Lexington, Massachusetts, USA; R.H.S. and K.R. are employees of Yumanity Therapeutics, Cambridge, Massachusetts, USA; T.E. is an employee of Takeda Pharmaceuticals, Cambridge, Massachusetts, USA; J.F. is retired. M.M., J.G., C.H. and R.M.N. are employees and shareholders of Neurimmune. S.S. was a site investigator for the PRIME study and received consultation fees from Biogen, and has received research support from Functional Neuromodulation, Merck, Genentech, Roche, Lilly, and Avid Radiopharmaceuticals, and consultation fees from Merck, Piramal, Lilly, Genentech, and Roche. He owns no stock options or royalties. Biogen has filed and licensed certain patent applications pertaining to Aducanumab.

Additional information

Reviewer Information Nature thanks L. Lannfelt, R. Thomas and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Extended data figures and tables

Extended Data Figure 2 Amyloid plaque reduction with aducanumab by baseline clinical stage and baseline ApoE ε4 status.

a, b, Analyses by baseline clinical stage were performed using ANCOVA for change from baseline with factors of: treatment, ApoE ε4 status (carrier and non-carrier) and baseline composite SUVR (a), and for analyses by ApoE ε4 status, using treatment and baseline composite SUVR (b). Adjusted mean ± s.e. ApoE ε4, apolipoprotein E ε4 allele; SUVR, standard uptake value ratio.

Extended Data Figure 3 Amyloid plaque reduction: regional analysis SUVR at week 54.

The boxed area indicates the six regions included in the composite score. *P < 0.05; **P < 0.01; ***P < 0.001 versus placebo; two-sided tests with no adjustments for multiple comparisons. Adjusted mean ± s.e. Analyses using ANCOVA. SUVR, standard uptake value ratio.

Extended Data Figure 4 Brain penetration of aducanumab after a single intraperitoneal administration in 22-month-old Tg2576 transgenic mice.

a, b, Aducanumab levels in plasma and brain (a), and plasma Aβ levels after a single dose (b; n = 4–5; mean ± s.e.). c, d, In vivo binding of aducanumab to amyloid deposits detected using a human IgG-specific secondary antibody (c), and ex vivo immunostaining with a pan-Aβ antibody on consecutive section (d). Examples of a compact Aβ plaque (solid arrow), diffuse Aβ deposit (dashed arrow), and CAA lesion (dotted arrow). CAA, cerebral amyloid angiopathy.

Extended Data Figure 5 Exposure following weekly dosing with chaducanumab in 9.5- to 15.5-month-old Tg2576 transgenic mice.

a, b, chaducanumab concentrations in plasma (a), or DEA-soluble brain extract (b) were measured in samples collected 24 h after the last dose in the ‘Chronic efficacy study’. Mean ± s.e. Dotted lines represent the limits of quantitation of each assay. c, Correlations of drug concentrations in plasma (open circles) or brain (open triangles) with administered dose. The average brain concentrations in the two groups receiving the lowest dose were below the limit of quantitation for that assay, which is indicated by a dotted line on the figure.

Extended Data Figure 6 Treatment with chaducanumab affects plaques of all sizes.

a, Following weekly dosing of chaducanumab in Tg2576 from 9.5–15.5 months of age, amyloid plaques were stained with 6E10 and quantified using Visiopharm software. b, Plaque size was defined by area, and coloured as follows: <125 μm2 (cyan), 125–250 μm2 (green), 250–500 μm2 (pink), and >500 μm2 (red). c, chaducanumab treatment was associated with a significant decrease in plaque number in all size ranges relative to vehicle-treated controls, with reductions of 58%, 68%, 68%, and 53% in the number of plaques for the <125 μm2, 125–250 μm2, 250–500 μm2, and >500 μm2 groups size, respectively. Mean ± s.e.; statistically significant differences from vehicle for each size range are indicated with asterisks; *P < 0.05, Mann–Whitney test.

Extended Data Figure 7 Enhanced recruitment of microglia to amyloid plaques following chaducanumab treatment and engagement of Fcγ receptors.

a, b, Brain sections from either PBS- or chaducanumab-treated mice (‘Chronic efficacy study’; 3 mg kg−1 group) were immunostained for Aβ (6E10; red) and a marker of microglia (Iba1; brown). c, The area of individual amyloid plaques was measured, and Iba1-stained microglia were grouped into two categories, either associated with plaques (within 25 μm of a plaque) or not associated with plaques (>25 μm from a plaque). Plaques with circumferences ≥ 70% surrounded by microglia were quantified and stratified based on plaque size. The fraction of plaques that were at least 70% surrounded by microglia was significantly greater in the chaducanumab-treated group (white bars) compared with the PBS control group (grey bars), for plaques ≥250 μm2. Mean ± s.e.; statistically significant differences from vehicle for each size range are indicated with asterisks; *P < 0.05, Bonferroni’s post hoc test following one-way analysis of variance. All quantifications were done using the Visiopharm software. d, e, FITC-labelled Aβ42 fibrils were incubated with different concentrations of the antibodies before adding to BV-2 microglia cell line (d), or primary microglia (e) for phagocytosis experiment measuring uptake of Aβ42 fibrils into the cells by FACS analysis. Mean ± s.d.

Extended Data Table 1 Change from baseline in amyloid PET SUVR values (a secondary endpoint at 6 months), and in exploratory clinical endpoints at the end of the placebo-controlled period (6-month data also shown for amyloid PET)

Full size table

Extended Data Table 2 Incidence of ARIA based on MRI data and ARIA-E patient disposition

Full size table

Extended Data Table 3 Pharmacokinetic data

Full size table

Extended Data Table 4 Change from baseline in amyloid PET SUVR values, CDR-SB, and MMSE at the end of the placebo-controlled period by absence/presence* of ARIA-E

Full size table

Supplementary information

Supplementary Information

This includes Supplementary Methods, a Supplementary Discussion and Results, and a list of the PRIME investigators. (PDF 249 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Sevigny, J., Chiao, P., Bussière, T. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease.Nature 537, 50–56 (2016). https://doi.org/10.1038/nature19323

Download citation